Evaluating CEO candidates’ ability to pivot can be challenging. This firm says it’s figured out how to measure CEO agility. How one CEO’s counter-cultural movement became Yondr Graham Dugoni's ...

Deploying accents and wigs, the Wicked star takes on all Bram Stoker’s characters, but the atmosphere lacks the fever or diabolicism required Bloody brilliant or toothless? Cynthia Erivo’s Dracula – ...

Leyla Bouzid’s third feature stars newcomer Eya Bouteraa as a Muslim lesbian returning home for a funeral, and Abbass as the mother unwilling to fully accept her. By Jordan Mintzer In a Whisper (À ...

A renewal of interest in meditation, spirituality, and mysticism is increasing, even as historic churches lament their own decline. Some Christians are finding conventional worship inadequate to ...

In a Whisper (À voix basse) is a fitting title for Tunisian director Leyla Bouzid's quietly effective third feature, which depicts the struggles of gays and lesbians in a country where being ...

Get the latest entertainment news with our free Culture newsletter It takes a moment for writer-director Bart Layton – a documentarian working here for the first time in pure fiction by adapting a Don ...

The U.S. Food and Drug Administration (FDA) refused to consider Moderna’s application for a new flu vaccine using mRNA technology, the company announced Tuesday, a decision that could delay the ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday. The move is the latest sign that the FDA, under Health Secretary Robert F.

Your why may not be what you think it is. by Jonathan Knowles, Tom Hunsaker, Hannah Grove and Alison James Today’s business leaders are under pressure to come up with a corporate purpose, much as they ...

TIOBE Index for February 2026: Top 10 Most Popular Programming Languages Your email has been sent February’s TIOBE Index shows a leaderboard that looks steady at first glance, but small shifts beneath ...

The Food and Drug Administration on Wednesday defended its rejection of Moderna’s mRNA-based flu vaccine application, saying the company’s clinical trial design put patients at risk. The FDA’s defense ...